USA-based specialty pharmaceutical firm Hospira and German companies Stada Arzneimittel AG and Bioceuticals, say they have established a development, manufacturing and distribution agreement focusing on a biosimilar version of the hormone erythropoietin.
Under the terms of the deal, Hospira has exclusive rights to Bioceuticals' EPO product in the USA, Canada and European Union, with the exclusion of Germany where it is entitled to semi-exclusive rights. In return, Bioceuticals, which was originally established by Stada, will receive an upfront payment of $21.0 million and up to $34.0 million in milestones based on regulatory approvals and sales goals.
Currently, the drug is being reviewed by the European Medicines Agency (EMEA) under a biosimilar marketing application and, if approved, could be launched for use in the field of dialysis by the end of 2007. Hospira added, however, that the sale of the product in the USA is not expected for several years due to the later expiration of current patents. In addition, Bioceuticals is conducting trials of the agent in support of an oncology indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze